Janssen Announces CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) Accepted for Accelerated Assessment in Europe for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will perform an accelerated assessment of the Marketing Authorisation Application (MAA) for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel). Accelerated assessment is granted by the CHMP when a medicinal product is expected to be of major public health interest and therapeutic innovation and can significantly reduce the review timelines to evaluate an MAA.1

Cilta-cel is an investigational BCMA-directed CAR-T therapy in development for the treatment of adults with relapsed and/or refractory multiple myeloma.2 CAR‑T therapy is a highly personalised technology where a patient’s own T-cells are reprogrammed to target and eradicate cancer.3

CP-205852 February 2021 “Multiple myeloma is a rare, incurable cancer, and has long been an area of focus
for Janssen,” said Sen Zhuang, M.D., Ph.D., Vice President, Clinical Research Development, Janssen Research & Development, LLC. “We are deeply committed to improving outcomes for patients with multiple myeloma, with a goal of delivering innovations that have the potential to expand current remission periods and improve quality of life.”
The cilta-cel MAA, which is targeted for submission in the first half of 2021, is supported by the positive results from the Phase 1b/2 CARTITUDE-1 study.2

The latest results from the CARTITUDE-1 study were presented at the American Society of Hematology (ASH) 2020 Annual Meeting.2 “We are excited that the potential clinical benefit of cilta-cel is being recognised and now look forward to working with the EMA to bring this highly innovative treatment to patients in need,” said Saskia De Haes, Vice President, EMEA Regulatory Affairs, Janssen R&D BE. This accelerated approval milestone in Europe follows the December 2020 announcement of a rolling submission of the Biologics License Application (BLA) for cilta-cel to the U.S. Food and Drug Administration (FDA).4
About CARTITUDE-1
CARTITUDE-1 (NCT03548207) is an ongoing Phase 1b/2, open-label, multicentre study evaluating the safety and efficacy of cilta-cel in adults with relapsed and/or refractory multiple myeloma, 99 percent of whom were refractory to the last line of treatment; 88 percent of whom were triple-class refractory, meaning their cancer did not, or no longer responds to an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody.2,5
The primary objective of the CARTITUDE-1 study is to characterise the safety and confirm the dose of cilta-cel, informed by the first-in-human study with LCARB38M CAR-T cells (LEGEND-2) and to evaluate the efficacy of cilta-cel with overall response as the primary endpoint.2,5

CP-205852 February 2021
About Ciltacabtagene Autoleucel (cilta-cel) Cilta-cel is an investigational chimeric antigen receptor T cell (CAR-T) therapy for the treatment of patients with multiple myeloma. The design comprises a structurally differentiated CAR-T with two BCMA-targeting single domain antibodies.2 CAR-T cells are an innovative approach to eradicating cancer cells by harnessing the power of a patient’s own immune system.6 BCMA is a protein that is highly expressed on myeloma cells.7

In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license and collaboration agreement with Legend Biotech to develop and commercialise cilta-cel.8 In May 2018, Janssen initiated a Phase 1b/2 CARTITUDE-1 trial (NCT03548207) to evaluate the efficacy and safety of cilta-cel in adults with relapsed and/or refractory multiple myeloma, informed by the LEGEND-2 study results.5,9 In April 2019, cilta-cel was granted PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA).10 PRIME offers enhanced interaction and early dialogue with developers of promising medicines, to optimise drug development plans and speed up evaluation of cutting-edge, scientific advances that target a high unmet medical need.11 In February 2020, the European Commission granted orphan designation for cilta-cel.12
About Multiple Myeloma
Multiple myeloma (MM) is an incurable blood cancer that starts in the bone
marrow and is characterised by an excessive proliferation of plasma cells.13
In Europe, more than 48,200 people were diagnosed with MM in 2018, and
more than 30,800 patients died.14 Around 50 percent of newly diagnosed
patients do not reach five-year survival,15,16 and almost 29 percent of
patients with multiple myeloma will die within one year of diagnosis.17
Although treatment may result in remission, unfortunately, patients will
most likely relapse as there is currently no cure.18 Refractory MM is when a
patient’s disease progresses within 60 days of their last therapy.19 Relapsed
cancer is when the disease has returned after a period of initial, partial or

CP-205852
February 2021
complete remission.19 While some patients with MM have no symptoms at
all, others are diagnosed due to symptoms that can include bone problems,
low blood counts, calcium elevation, kidney problems or infections.20
Patients who relapse after treatment with standard therapies, including
protease inhibitors and immunomodulatory agents, have poor prognoses
and require new therapies for continued disease control.21
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the
Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that
future a reality for patients everywhere by fighting sickness with science,
improving access with ingenuity, and healing hopelessness with heart. We focus
on areas of medicine where we can make the biggest difference: Cardiovascular
& Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience,
Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com/emea. Follow us at
www.twitter.com/janssenEMEA for our latest news. Janssen Pharmaceutica NV,
Janssen Research & Development, LLC, Janssen R&D BE, and Janssen Biotech,
Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
# # #
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private
Securities Litigation Reform Act of 1995 regarding product development and the
potential benefits and treatment impact of ciltacabtagene autoleucel. The reader
is cautioned not to rely on these forward-looking statements. These statements
are based on current expectations of future events. If underlying assumptions
prove inaccurate or known or unknown risks or uncertainties materialise, actual
results could vary materially from the expectations and projections of Janssen
Pharmaceutica NV and/or any of the other Janssen Pharmaceutical Companies
and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to:
challenges and uncertainties inherent in product research and development,
including the uncertainty of clinical success and of obtaining regulatory approvals;
uncertainty of commercial success; manufacturing difficulties and delays;
competition, including technological advances, new products and patents attained
by competitors; challenges to patents; product efficacy or safety concerns
resulting in product recalls or regulatory action; changes in behavior and spending
patterns of purchasers of health care products and services; changes to applicable

CP-205852
February 2021
laws and regulations, including global health care reforms; and trends toward
health care cost containment. A further list and descriptions of these risks,
uncertainties and other factors can be found in Johnson & Johnson’s Annual Report
on Form 10-K for the fiscal year ended December 29, 2019, including in the
sections captioned “Cautionary Note Regarding Forward-Looking Statements” and
“Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report
on Form 10-Q, and the company’s subsequent filings with the Securities and
Exchange Commission. Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. None of the Janssen
Pharmaceutical Companies nor Johnson & Johnson undertakes to update any
forward-looking statement as a result of new information or future events or
developments.

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post